• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Addison’s Disease Market

    ID: MRFR/Pharma/5165-HCR
    90 Pages
    Rahul Gotadki
    October 2025

    Addison’s Disease Market Research Report by Diagnosis (Laboratory Testing and Imaging Tests), Treatment (Oral Corticosteroid and Corticosteroid Injections), End User (Hospitals and Clinics, Diagnostic Laboratories, and Others)-Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Addison’s Disease Market Infographic
    Purchase Options

    Addison’s Disease Market Summary

    The Global Addison's Disease Market is projected to experience substantial growth from 2.34 USD Billion in 2024 to 7.29 USD Billion by 2035.

    Key Market Trends & Highlights

    Addison's Disease Key Trends and Highlights

    • The market is expected to grow at a compound annual growth rate of 10.88% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 7.29 USD Billion, indicating robust expansion.
    • In 2024, the market is valued at 2.34 USD Billion, laying a strong foundation for future growth.
    • Growing adoption of innovative treatment options due to increasing awareness of Addison's Disease is a major market driver.

    Market Size & Forecast

    2024 Market Size 2.34 (USD Billion)
    2035 Market Size 7.29 (USD Billion)
    CAGR (2025-2035) 10.88%

    Major Players

    Pfizer Inc, Boehringer Ingelheim International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline plc, Merck KGaA, Lupin Pharmaceuticals, Inc, Abbott, Amgen Limited & Amgen Ireland Limited, Bayer AG, Biogen, Eli Lilly and Company, Novartis AG, Diurnal, Switzer Life science Pvt. Ltd

    Addison’s Disease Market Drivers

    Market Growth Chart

    Development of Targeted Therapies

    The emergence of targeted therapies is reshaping the Global Addison's Disease Market Industry. Pharmaceutical companies are increasingly focusing on developing medications that specifically address the hormonal deficiencies associated with Addison's disease. These targeted treatments aim to improve patient outcomes by providing more effective management of symptoms. As research progresses, new therapies are expected to enter the market, potentially increasing the overall market size. By 2035, the market is anticipated to reach 7.29 USD Billion, driven by the introduction of innovative treatment options that cater to the unique needs of Addison's disease patients.

    Advancements in Diagnostic Techniques

    Innovations in diagnostic methodologies are significantly impacting the Global Addison's Disease Market Industry. Enhanced imaging techniques and hormonal assays facilitate earlier and more accurate diagnosis of Addison's disease. For instance, the introduction of advanced blood tests allows for the precise measurement of cortisol levels, leading to timely intervention. As diagnostic capabilities improve, healthcare providers can identify patients sooner, which may lead to better management of the disease. This trend is likely to contribute to the market's growth, as early diagnosis correlates with improved patient outcomes and increased demand for treatment options.

    Rising Prevalence of Addison's Disease

    The Global Addison's Disease Market Industry is experiencing growth due to the increasing prevalence of Addison's disease. This condition, characterized by insufficient production of adrenal hormones, affects approximately 60 to 100 individuals per million globally. As awareness of this rare disorder rises, more patients are being diagnosed, contributing to market expansion. The growing number of diagnosed cases is expected to drive demand for treatment options, thereby enhancing the market's value. In 2024, the market is projected to reach 2.34 USD Billion, reflecting the urgent need for effective therapies and management strategies.

    Growing Awareness and Education Initiatives

    The Global Addison's Disease Market Industry benefits from increased awareness and educational initiatives aimed at both healthcare professionals and the general public. Organizations and advocacy groups are actively promoting information about Addison's disease, its symptoms, and treatment options. This heightened awareness encourages individuals experiencing symptoms to seek medical attention, leading to more diagnoses. As a result, the market is likely to see an uptick in demand for therapies and management solutions. The ongoing education efforts are crucial in fostering a better understanding of the disease, which may ultimately enhance patient care and treatment adherence.

    Increased Investment in Healthcare Infrastructure

    Investment in healthcare infrastructure is a critical driver for the Global Addison's Disease Market Industry. Governments and private entities are allocating resources to enhance healthcare facilities, improve access to care, and support research initiatives. This investment is particularly vital in regions where healthcare access is limited, as it enables better diagnosis and treatment of Addison's disease. Improved healthcare infrastructure can lead to a more robust supply chain for medications and therapies, ultimately benefiting patients. As healthcare systems evolve, the market is likely to experience growth, reflecting the positive impact of these investments on patient care.

    Key Companies in the Addison’s Disease Market market include

    Industry Developments

    Lupin Ltd (Lupin) is a pharmaceutical company that produces and markets generic and branded pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Cardiovascular, diabetes etc are all part of the company's product range. Oral, ophthalmic, dermatological, and inhalation product research are key priorities for the organization. The company's operations are reported under a single segment, Pharmaceuticals. Formulations, active pharmaceutical ingredients (APIs), generic formulations, and biotechnology products are all part of Lupin's business.

    In August 2015, Amgen, a biotechnology corporation located in the United States, launched its significantly enlarged production plant in Dun Laoghaire, Ireland. The $300 million expansion expanded manufacturing facilities to the existing factory, enhancing its capabilities and positioning it as a major hub for Amgen's global operations. The move was part of Amgen's long-term plan to manufacture all of its pharmaceuticals at the Dun Laoghaire facility, ensuring a steady supply of Amgen's medicines for severely sick patients across the world.

    Global Addison’s Disease Market, by Diagnosis

      • Laboratory Tests
        • Blood Tests
        • ACTH Stimulation Tests
        • Other Tests
      • Imaging Tests
        • Chest Radiography
        • CT Scan

    Global Addison’s Disease Market, by Treatment

      • Oral Corticosteroid
      • Corticosteroid Injections

    Global Addison’s Disease Market, by End User

      • Hospitals and Clinics
      • Diagnostic Laboratories
      • Other End Users

    Global Addison’s Disease Market, by Region

      • Americas
        • North America
          • US
          • Canada
        • South America
      • Europe
        • Western Europe
          • Germany
          • France
          • Italy
          • Spain
          • UK
          • Rest of Western Europe
        • Eastern Europe
      • Asia-Pacific
        • Japan
        • China
        • India
        • Australia
        • South Korea
        • Rest of Asia-Pacific
      • Middle East & Africa
        • Middle East
        • Africa

    Global Addison’s Disease Market, by Key Players

      • Pfizer Inc.
      • Boehringer Ingelheim International GmbH
      • Shire
      • Tocris Bioscience
      • GlaxoSmithKline Plc
      • Merck KGaA
      • Lupin Pharmaceuticals, Inc.
      • Abbott
      • Amgen Limited & Amgen Ireland Limited

    Future Outlook

    Addison’s Disease Market Future Outlook

    The Global Addison's Disease Market is projected to grow at a 10.88% CAGR from 2024 to 2035, driven by increasing awareness, advancements in treatment options, and rising prevalence rates.

    New opportunities lie in:

    • Develop innovative therapies targeting adrenal insufficiency to enhance patient outcomes.
    • Leverage telemedicine for remote monitoring and management of Addison's Disease patients.
    • Invest in educational campaigns to raise awareness and improve early diagnosis rates.

    By 2035, the Addison's Disease Market is expected to exhibit robust growth, reflecting advancements in treatment and increased patient engagement.

    Report Scope

    Report Attribute/Metric Details
      Market Size   USD 5.35 Billion
      CAGR   2024-2032:10.84%
      Base Year   2023
      Forecast Period   2032
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Diagnosis, Treatment And End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors    Pfizer Inc., Boehringer Ingelheim International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline plc, Merck KGaA, Lupin Pharmaceuticals, Inc., Abbott, Amgen Limited & Amgen Ireland Limited, Bayer AG, Biogen, Eli Lilly and Company, Novartis AG, Diurnal, Switzer Life science Pvt. Ltd
      Key Market Opportunities   R&D Activities
      Key Market Drivers ·  Growing prevalence of Addison’s disease ·  Increasing awareness of the disease ·  Rising healthcare expenditure

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    At what CAGR is the Addison’s disease market projected to grow during the forecast period?

    The Addison’s disease market is projected to grow at a 10.84% CAGR between 2024-2032.

    Which region is projected to command the largest share in the Addison’s disease market?

    North America is projected to command the largest share in the Addison’s disease market.

    Which treatment segment will dominate the Addison’s disease market?

    Oral corticosteroids segment will dominate the Addison’s disease market.

    What are the key factors driving the Addison’s disease market?

    Rising healthcare expenditure and growing awareness about the disease is boosting market growth.

    Which factors may limit Addison’s disease market growth?

    Inability to diagnose Addison’s disease may limit market growth.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials